Evaluating Pharmaceuticals for Health Policy and Reimbursement

Development of marketing authorisation procedures for pharmaceuticals.

Interpreting clinical evidence.

International pharmaceutical policy - health creation or wealth creation?.

The development of fourth hurdle policies around the world.

Economic modelling in drug reimbursement.

Priority-setting in health care: matching decision criteria with policy objectives.

The tensions in licensing and reimbursement decisions: the case of riluzole for amyotrophic lateral.

sclerosis.

Relationship between stakeholders: managing the war of the words.

Medicines and the media: good information or misleading hype?.

How to promote quality use of cost-effective medicines.

Making it happen and making it sustainable.

Pricing of pharmaceuticals.

Evaluating pharmaceuticals for health policy in low and middle income country settings